# Comparative Study of the Pharmacokinetics and Bioequivalence of Two Flupentixol Formulations

> **NCT02660840** · PHASE1 · COMPLETED · sponsor: **H. Lundbeck A/S** · enrollment: 84 (actual)

## Conditions studied

- Bioequivalence Study in Healthy Subjects

## Interventions

- **DRUG:** 0.5 mg Flupentixol film-coated tablet (test treatment)
- **DRUG:** 1 mg Flupentixol film-coated tablet (test treatment)
- **DRUG:** 5 mg Flupentixol film-coated tablet (test treatment)
- **DRUG:** 0.5 mg Flupentixol coated tablet (reference treatment)
- **DRUG:** 1 mg Flupentixol coated tablet (reference treatment)
- **DRUG:** 5 mg Flupentixol coated tablet (reference treatment)

## Key facts

- **NCT ID:** NCT02660840
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2016-06
- **Final completion:** —
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2016-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02660840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02660840, "Comparative Study of the Pharmacokinetics and Bioequivalence of Two Flupentixol Formulations". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02660840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*